Compare Dishman Pharma with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs DR. DATSONS LABS - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA DR. DATSONS LABS DISHMAN PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 25.1 -10.9 - View Chart
P/BV x 3.3 0.2 2,061.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
DR. DATSONS LABS
Mar-14
DISHMAN PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs374126 298.1%   
Low Rs12931 417.2%   
Sales per share (Unadj.) Rs197.8133.0 148.7%  
Earnings per share (Unadj.) Rs21.20.2 13,987.0%  
Cash flow per share (Unadj.) Rs34.76.6 525.5%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.9128.8 139.7%  
Shares outstanding (eoy) m80.6931.66 254.9%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x1.30.6 216.2%   
Avg P/E ratio x11.9516.1 2.3%  
P/CF ratio (eoy) x7.211.8 61.2%  
Price / Book Value ratio x1.40.6 230.2%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3062,477 819.6%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,35556 9,562.3%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,9614,211 379.1%  
Other income Rs m26579 337.2%   
Total revenues Rs m16,2264,289 378.3%   
Gross profit Rs m4,103569 721.6%  
Depreciation Rs m1,091204 533.6%   
Interest Rs m944430 219.5%   
Profit before tax Rs m2,33413 18,374.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m1-2 -61.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6246 10,223.0%   
Profit after tax Rs m1,7115 35,647.9%  
Gross profit margin %25.713.5 190.4%  
Effective tax rate %26.748.0 55.6%   
Net profit margin %10.70.1 9,404.2%  
BALANCE SHEET DATA
Current assets Rs m11,0186,852 160.8%   
Current liabilities Rs m9,5176,711 141.8%   
Net working cap to sales %9.43.3 280.8%  
Current ratio x1.21.0 113.4%  
Inventory Days Days110161 68.7%  
Debtors Days Days35318 10.9%  
Net fixed assets Rs m16,3043,673 443.9%   
Share capital Rs m161317 51.0%   
"Free" reserves Rs m12,9073,761 343.2%   
Net worth Rs m14,5164,078 356.0%   
Long term debt Rs m4,1891,671 250.7%   
Total assets Rs m29,80512,633 235.9%  
Interest coverage x3.51.0 337.1%   
Debt to equity ratio x0.30.4 70.4%  
Sales to assets ratio x0.50.3 160.7%   
Return on assets %8.93.4 258.7%  
Return on equity %11.80.1 10,013.7%  
Return on capital %17.57.7 228.5%  
Exports to sales %24.822.9 108.3%   
Imports to sales %3.714.3 26.1%   
Exports (fob) Rs m3,956964 410.4%   
Imports (cif) Rs m596602 99.1%   
Fx inflow Rs m4,952964 513.6%   
Fx outflow Rs m697607 114.8%   
Net fx Rs m4,255357 1,192.1%   
CASH FLOW
From Operations Rs m2,7861,345 207.2%  
From Investments Rs m-1,529-2,256 67.8%  
From Financial Activity Rs m-941-1,200 78.4%  
Net Cashflow Rs m316-2,111 -15.0%  

Share Holding

Indian Promoters % 61.4 4.5 1,355.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.0 -  
FIIs % 12.7 1.4 940.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 94.1 23.5%  
Shareholders   46,261 20,807 222.3%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Corrects Over 750 Points; Nifty Falls below 8,400-Mark(10:30 am)

Share markets in India have extended early losses tracking weakness in global peers, amid heightened worries of COVID-19 virus outbreak.

Related Views on News

Most Popular

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - SANOFI INDIA COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS